Taysha Gene Therapies, Inc. Financials
Taysha Gene Therapies, Inc. (TSHA) reported $9.8M in revenue for fiscal year 2025, up 17.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not revenue, is funding a research-heavy operating model while cash reserves rebuild the balance sheet.
In FY2025, a$274.6M financing inflow more than covered the$93.1M operating cash burn, so liquidity improved for funding reasons rather than because the business became self-funding. That same capital reset equity from just$949K in FY2022 to$246.9M in FY2025, meaning the stronger balance sheet reflects recapitalization more than growth in the current revenue base.
With
Spending remains development-led: FY2025 R&D was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Taysha Gene Therapies, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Taysha Gene Therapies, Inc. scores 9.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.0B) relative to total liabilities ($96.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Taysha Gene Therapies, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Taysha Gene Therapies, Inc. reported a net loss of $109.0M while operations used $93.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Taysha Gene Therapies, Inc. reported an operating loss of $110.5M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Taysha Gene Therapies, Inc. generated $9.8M in revenue in fiscal year 2025. This represents an increase of 17.3% from the prior year.
Taysha Gene Therapies, Inc.'s EBITDA was -$109.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.2% from the prior year.
Taysha Gene Therapies, Inc. reported -$109.0M in net income in fiscal year 2025. This represents a decrease of 22.1% from the prior year.
Taysha Gene Therapies, Inc. earned -$0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5.6% from the prior year.
Cash & Balance Sheet
Taysha Gene Therapies, Inc. recorded an outflow of $93.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 15.0% from the prior year.
Taysha Gene Therapies, Inc. held $319.8M in cash against $50.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Taysha Gene Therapies, Inc.'s ROE was -44.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 80.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Taysha Gene Therapies, Inc. invested $86.4M in research and development in fiscal year 2025. This represents an increase of 30.9% from the prior year.
Taysha Gene Therapies, Inc. invested $738K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 97.3% from the prior year.
Not reported for fiscal year 2025.
TSHA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | $9.8M+17.3% | $8.3M-46.1% | $15.5M+517.5% | $2.5M | N/A | N/A |
| R&D Expenses | N/A | $86.4M+30.9% | $66.0M+16.2% | $56.8M-37.7% | $91.2M-30.9% | $131.9M+313.7% | $31.9M |
| SG&A Expenses | N/A | $33.9M+17.0% | $29.0M-3.6% | $30.0M-19.6% | $37.4M-9.6% | $41.3M+272.0% | $11.1M |
| Operating Income | N/A | -$110.5M-20.8% | -$91.5M-26.3% | -$72.4M+55.4% | -$162.4M+6.2% | -$173.3M-302.9% | -$43.0M |
| Interest Expense | N/A | $63K-38.2% | $102K-98.0% | $5.0M+31.6% | $3.8M+166.0% | $1.4M+5000.0% | $28K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | N/A | $0 |
| Net Income | N/A | -$109.0M-22.1% | -$89.3M+20.0% | -$111.6M+32.8% | -$166.0M+4.9% | -$174.5M-190.8% | -$60.0M |
| EPS (Diluted) | — | -$0.34+5.6% | -$0.36 | -$0.96 | -$3.78+18.5% | -$4.64 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TSHA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $343.3M+114.1% | $160.4M-7.2% | $172.7M+36.8% | $126.3M-41.0% | $214.0M-17.4% | $258.9M |
| Current Assets | $324.6M+128.4% | $142.1M-5.2% | $149.9M+55.4% | $96.4M-39.6% | $159.6M-38.1% | $257.9M |
| Cash & Equivalents | $319.8M+130.0% | $139.0M-3.4% | $143.9M+63.8% | $87.9M-41.1% | $149.1M-40.7% | $251.3M |
| Total Liabilities | $96.4M+8.5% | $88.8M-9.2% | $97.8M-22.0% | $125.3M+5.7% | $118.6M+1464.5% | $7.6M |
| Current Liabilities | $26.6M+1.2% | $26.2M-28.6% | $36.8M-41.5% | $62.8M+21.3% | $51.7M+625.9% | $7.1M |
| Long-Term Debt | $50.1M+14.0% | $43.9M+8.5% | $40.5M+6.7% | $38.0M+2.1% | $37.2M | N/A |
| Total Equity | $246.9M+245.2% | $71.5M-4.6% | $74.9M+7796.4% | $949K-99.0% | $95.4M-62.0% | $251.3M |
| Retained Earnings | -$711.3M-18.1% | -$602.3M-17.4% | -$513.0M-27.8% | -$401.4M-70.4% | -$235.6M-285.5% | -$61.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TSHA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$132.2M | -$93.1M-14.6% | -$81.2M-11.2% | -$73.0M+17.4% | -$88.4M+24.5% | -$117.0M-280.9% | -$30.7M |
| Capital Expenditures | $381K | $738K+97.3% | $374K-90.3% | $3.9M-81.2% | $20.6M+34.7% | $15.3M+18563.4% | $82K |
| Free Cash Flow | -$132.6M | -$93.8M-15.0% | -$81.6M-6.1% | -$76.9M+29.5% | -$109.0M+17.6% | -$132.3M-329.5% | -$30.8M |
| Investing Cash Flow | -$3.3M | -$604K-66.4% | -$363K+95.1% | -$7.4M+70.5% | -$24.9M-15.7% | -$21.6M-137.3% | -$9.1M |
| Financing Cash Flow | $275.7M | $274.6M+258.1% | $76.7M-43.8% | $136.4M+161.8% | $52.1M+33.3% | $39.1M-86.6% | $291.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TSHA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -1130.7% | -1097.5% | -468.8% | -6492.7% | N/A | N/A |
| Net Margin | -1115.3% | -1071.6% | -722.1% | -6635.3% | N/A | N/A |
| Return on Equity | -44.1%+80.7pp | -124.8%+24.0pp | -148.9%+17344.7pp | -17493.6%-17310.6pp | -183.0%-159.1pp | -23.9% |
| Return on Assets | -31.8%+23.9pp | -55.7%+8.9pp | -64.6%+66.9pp | -131.5%-49.9pp | -81.6%-58.4pp | -23.2% |
| Current Ratio | 12.23+6.8x | 5.42+1.3x | 4.08+2.5x | 1.54-1.5x | 3.08-33.1x | 36.17 |
| Debt-to-Equity | 0.20-0.4x | 0.61+0.1x | 0.54-39.5x | 40.01+39.6x | 0.39+0.4x | 0.03 |
| FCF Margin | -960.1% | -979.2% | -497.6% | -4356.9% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Taysha Gene Therapies, Inc. Ranks
Frequently Asked Questions
What is Taysha Gene Therapies, Inc.'s annual revenue?
Taysha Gene Therapies, Inc. (TSHA) reported $9.8M in total revenue for fiscal year 2025. This represents a 17.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Taysha Gene Therapies, Inc.'s revenue growing?
Taysha Gene Therapies, Inc. (TSHA) revenue grew by 17.3% year-over-year, from $8.3M to $9.8M in fiscal year 2025.
Is Taysha Gene Therapies, Inc. profitable?
No, Taysha Gene Therapies, Inc. (TSHA) reported a net income of -$109.0M in fiscal year 2025.
What is Taysha Gene Therapies, Inc.'s EBITDA?
Taysha Gene Therapies, Inc. (TSHA) had EBITDA of -$109.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Taysha Gene Therapies, Inc. have?
As of fiscal year 2025, Taysha Gene Therapies, Inc. (TSHA) had $319.8M in cash and equivalents against $50.1M in long-term debt.
What is Taysha Gene Therapies, Inc.'s return on equity (ROE)?
Taysha Gene Therapies, Inc. (TSHA) has a return on equity of -44.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Taysha Gene Therapies, Inc.'s free cash flow?
Taysha Gene Therapies, Inc. (TSHA) recorded an outflow of $93.8M in free cash flow during fiscal year 2025. This represents a -15.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Taysha Gene Therapies, Inc.'s operating cash flow?
Taysha Gene Therapies, Inc. (TSHA) recorded an outflow of $93.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Taysha Gene Therapies, Inc.'s total assets?
Taysha Gene Therapies, Inc. (TSHA) had $343.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Taysha Gene Therapies, Inc.'s capital expenditures?
Taysha Gene Therapies, Inc. (TSHA) invested $738K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Taysha Gene Therapies, Inc. spend on research and development?
Taysha Gene Therapies, Inc. (TSHA) invested $86.4M in research and development during fiscal year 2025.
What is Taysha Gene Therapies, Inc.'s current ratio?
Taysha Gene Therapies, Inc. (TSHA) had a current ratio of 12.23 as of fiscal year 2025, which is generally considered healthy.
What is Taysha Gene Therapies, Inc.'s debt-to-equity ratio?
Taysha Gene Therapies, Inc. (TSHA) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Taysha Gene Therapies, Inc.'s return on assets (ROA)?
Taysha Gene Therapies, Inc. (TSHA) had a return on assets of -31.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Taysha Gene Therapies, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Taysha Gene Therapies, Inc. (TSHA) held $319.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $93.1M over that year. Dividing the one by the other, the reported balance equals about 41 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Taysha Gene Therapies, Inc.'s Altman Z-Score?
Taysha Gene Therapies, Inc. (TSHA) has an Altman Z-Score of 9.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Taysha Gene Therapies, Inc.'s Piotroski F-Score?
Taysha Gene Therapies, Inc. (TSHA) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Taysha Gene Therapies, Inc.'s earnings high quality?
Taysha Gene Therapies, Inc. (TSHA) reported a net loss of $109.0M while operations used $93.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Taysha Gene Therapies, Inc. cover its interest payments?
Taysha Gene Therapies, Inc. (TSHA) reported an operating loss of $110.5M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. (TSHA) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.